AI FOR DRUG DISCOVERY, BIOMARKER DEVELOPMENT AND ADVANCED R&D LANDSCAPE OVERVIEW 2018 / Q2

Companies - 100
Investors - 220
Corporations - 30
R&D Centers - 20
Conferences - 20

www.dkv.global/analytics

DEEP KNOWLEDGE ANALYTICS

AI for Drug Discovery, Biomarker Development and Advanced R&D Landscape Overview 2018 / Q2

Table of Contents

Table of Contents

AI for Drug Discovery, Biomarker Development and Advanced R&D Landscape / 2018 Q2

Companies - 100
Investors - 220
Corporations - 30

Drug Discovery

Advanced R&D

Investors

AI Companies

Corporations

DEEP KNOWLEDGE ANALYTICS

Diversification of AI for R&D and Drug Discovery process

Companies - 100
Investors - 220

Companies

Investors

Design Preclinical Experiments

EUROTOS

AFORE CAPITAL
SYNDICATE ROOM
golden
Healthbox
Boundary Capital
inovia
IQ CAPITAL
LCIF
Gradient Ventures

Preclinical Experiment Execution

novoheart
ECL
EMERALD CLOUDLAB
SYNTHACE
SOFINNOVA PARTNERS
UK INNOVATION & SCIENCE SEED FUND
BIOECONOMY CAPITAL

Data Aggregation & Analysis

Meta
MediBic Group
insitro
BioSymetrics
nf
Biorelate
Evid Science
INNOPLEXUS
THOUGHTSPOT
KYNDI
IRIS.AI
Plex
ef.
techammer
G/
MITS FUND
KPCB
HCS
VTF CAPITAL
MATRIX
AllBright
WHITE CLOUD
PITCH PALACE
LIFE SCIENCES FUND
500
matrix
servicenow
DFJ GROWTH
WARBURG PINCUS
FOUNDERS FUND
Zappos
SUTTER HILL VENTURES
MAYO CLINIC
CATHAY
WESTCOTT LLC
PivotNorth
DIGITAL science
Zillionize
NJF
BOE
OtiumCapital
GEODESIC CAPITAL
BEAST VENTURES
PLUG AND PLAY
khosla ventures
Lenovo
BAKKEN & BÆCK
GOY
CREATIVE DESTRUCTION
GAORONG CAPITAL
UpHonest Capital
LIGHTSPEED VENTURE PARTNERS
LaunchCapital
illumina
ZhenFund
CITRIX
CapitalOne
FOUNDERS FACTORY
JHUNTHOLDINGS
BOLD CAPITAL PARTNERS
InnoSpring
COMCAST VENTURES
Darling VENTURES
kima ventures
Horizons Ventures

Drug Design

ATOM
XtalPi
ProteinQure
IKTOS
COTINGA PHARMACEUTICALS
arbor
celsius
DATAVANT
IBM
GTN LTD
bactevo
BIOAGE
engine
Numerate
VERGE genomics
PEPTICOM
JUVENESCENCE.AI
SPRING DISCOVERY
BenevolentAI
NuMedii
NURITAS
RESONANT THERAPEUTICS
Mind the Byte
CloudPharmaceuticals
Exscientia
Atomwise
twoXAR
Globavir
VIRVIO
BERG
CYTOX
e-Therapeutics plc
ENVISAGENICS
QUANTITATIVE MEDICINE
teselagen
deep genomics
NIH
WuXi AppTec
true ventures
Empire State Development
nest
nesta
Tencent 腾讯
Pavilion
EDB singapore
DEEP KNOWLEDGE VENTURES
DRAPER ASSOCIATES
Pear
MASA Life Science Ventures
Foundation CAPITAL
HANNAM
Karlin
WrenCapital
LB Investment
CUBE VENTURES
ENTERPRISE IRELAND
LILLYVENTURES
EPIC
TWO SIGMA VENTURES
sorrento THERAPEUTICS
THIRD ROCK VENTURES
riiden
SERAPH GROUP
LanzaTech
CLAREMONT CREEK VENTURES
B Capital Group
Dynamic Capital
Data Collective
Baidu 百度
ACCELERATE LONG ISLAND
Felicis Ventures
GRAND CENTRAL TECH
UPSHER-SMITH
11.2 Capital
AME CLOUD VENTURES
DOLBY FAMILY VENTURES
Bloomberg
THIEL FOUNDATION
A-LEVEL Capital
Atinum Investment
atlas venture
LANSDOWNE PARTNERS
ANDREESSEN HOROWITZ
SoftBank Ventures Korea
3X
CULTIVIAN SANDBOX
VENTURES
SENECA
woodford
Start X
GreenSky
Frontier IP Group
Y Combinator
renren
ALS INVESTMENT FUND
Perivoli
Caffeinated Capital
MGV
crowdcube
NEW PROTEIN
TEEC ANGEL FUND
Stanford University
GREAT OAKS VENTURE CAPITAL
AGENT CAPITAL
Agoranov
SVAngel
pentech
FREE
NEWWAVEVENTURES
CASDIN CAPITAL
STARTUP HEALTH
OS FUND
Alphabet
UNIVERSITY INNOVATION ALLIANCE

Clinical Trial Design, Optimization, Recruitment

antidote
BULLFROG AI
nQ
inato
WINTERLIGHT
Mendel.ai
REVEAL
clinithink
Athelas
DEEP 6 AI
trials.ai
CLOUD MEDX
UNSHACKLED VENTURES
REFACTOR CAPITAL
realventures
BAIRD
GLOBAL HEALTH INNOVATION
dcm
Amadeus Capital Partners
20
DORM ROOM FUND
Pritzker Group VENTURE CAPITAL
ChinaEquity 信中利
bootstrap labs
TVP
TRIBECA VENTURE PARTNERS
SMEDVIG
NLV
HACKING HEALTH
L2 VENTURES
serena
FAIRHAVEN CAPITAL
INDIE.BIO
initialized
SEQUOIA
Banc
AMGEN
DHVC
FLY VENTURES
MITSUI&CO.
50
Celgene
bdc
ALEXANDRIA
8VC
CAMBIA
GNS HEALTHCARE
HERITAGE PROVIDER NETWORK
PALMDRIVE
DRAPER DRAGON
SVTECH VENTURES
KdT Ventures
pillar
FundersClub

Repurpo-sing Existing Drugs

Biovista
Lantern Pharma
healx
BioXcel
RECURSION
Qrativ
AcuraStem
PHARNEXT
1 square 1 bank
Menlo
Truffle Capital
OBVIOUS VENTURES
HEALTH WILDCATTERS
AURINVEST
EPIC VENTURES
luxcapital
ADVANTAGE CAPITAL PARTNERS
MUBADALA
Atinum Investment
Bios | Partners
crv
WILD BASIN INVESTMENTS LLC
KOREA
LB Investment

Researching Mechanisms of Disease

PHENOMIC AI
ReviveMed
Virogin
CytoReason
FDNA
STRUCTURA BIOTECHNOLOGY
SOFINNOVA
Endure
BIOECONOMY CAPITAL
MC
UK INNOVATION & SCIENCE SEED FUND
NEWDO
TECHU
RIVAS CAPITAL
WORLDQUANT VENTURES

DEEP KNOWLEDGE ANALYTICS

AI for Drug Discovery, Biomarker Development and Advanced R&D Landscape / 2018 Q2

Companies - 100
Investors - 220
Corporations - 30

Regional Position

Investors

AI Companies

Corporations

DEEP KNOWLEDGE ANALYTICS

Leading
IT and Tech Corporations / AI Companies / Pharma Corporations
Advanced AI in Healthcare and Drug Discovery



DEEP KNOWLEDGE ANALYTICS

AI for Advanced R&D and Drug Discovery 2018 / Q2

In the end of 2017 our analytical department released its inaugural report on the state of AI for Drug Discovery industry, entitled "AI for Drug Discovery Landscape Overview 2017".

In April 2018 we released a subsequent report entitled "AI for Drug Discovery & Advanced R&D Q1 2018".

The present report is a significantly extended edition with more in-depth coverage of specific topics, and which has aggregated all important industry developments occurring in the second financial quarter of 2018.

The second quarter of 2018 saw major changes, significant investments, acquisitions, and the establishment of substantial joint ventures. This serves as a stark reminder of how fast the AI for Drug Discovery, Biomarker Development and Advanced R&D sector is advancing. Many trends noted in our last report have continued and intensified, while other new trends have emerged as well.



Pharma Efficiency is Declining Steadily



>$2.6B TO DEVELOP ONE DRUG

92% FAILURE RATE IN CLINICAL TRIALS

Bernstein Research: The Long View - R&D Productivity, 2010

46 NEW DRUGS launched in 2014

Source: adapted from Insilico Medicine investor presentations, www.insilico.com

GLOBAL SALES:

>$1 Trillion

GLOBAL R&D:

>$150 Billion

>$2.6B TO DEVELOP ONE DRUG

92% FAILURE RATE IN CLINICAL TRIALS



Source: adapted from Insilico Medicine investor presentations, www.insilico.com

THE BIOPHARMACEUTICAL RESEARCH AND DEVELOPMENT PROCESS



Source: Biopharmaceutical Research & Development, PRMA http://phrma-docs.phrma.org/sites/default/files/pdf/rd_brochure_022307.pdf

The "heat map" of AI potential value for various R&D areas



The Application of AI for Advanced R&D

Generate Novel Drug Candidates

- Analyze data sets, form hypotheses and generate novel insights
- Identify novel drug candidates
- Analyze data from patient samples in both healthy and diseased states to generate novel biomarkers and therapeutic targets
- Predict binding affinity and other pharmacological properties of molecules
- Allow filtering for drug-like properties of molecules
- Reduce complexity in protein design

Aggregate and Synthesize Information

- Extract knowledge from literature
- Generate insights from thousands of unrelated data sources
- Improve decision-making
- Eliminate blind spots in research
- Identify competitive whitespace

Repurpose Existing Drugs

- Rapidly identify new indications for many known drugs
- Match existing drugs with rare diseases
- Conduct experimental biology at scale by testing 1000+ of compounds on 100+ of cellular disease models in parallel
- Generate novel biomarkers and therapeutic targets

Design and Run Preclinical Experiments

- Reduce time, money, and uncertainty in planning experiments
- Decode open- and closed-access data on reagents and get actionable insights
- Automate selection, manipulation, and analysis of cells
- Expedite development of cell lines and automate manufacturing of cellular therapeutics
- Automate sample analysis with a robotic cloud laboratory

Clinical Trials

- Optimize clinical trial study design
- Transform diverse streams of biomedical and healthcare data into computer models representative of individual patients
- Deliver personalized medicine at scale, by revealing optimal health interventions for individual patients
- Analyze medical records to find patients for clinical trials
- Automate matching cancer patients to clinical trials through personal medical history and genetic analysis
- Improve pathology analysis
- Identify patients that would benefit from novel therapies

Computation-based Drug Discovery

Millions of Compounds



1000s of Compounds

Clinical Trials FDA Approval Process

Synthesize new Chemical Compounds

Robot-assisted screening *High Throughput Screening*

Testing for Efficacy, Side Effects, Safety

Computational Chemistry

- Synthesize compounds based on similarity



Virtual Screening

- Check if compounds bind to target proteins

Lead Optimization

- Modify chemicals to improve efficacy



1

Source: https://blogs.nvidia.com/blog/2010/01/22/accelerating-the-pace-of-drug-discovery-using-gpus/

Regional Comparison of AI for Drug Discovery Companies/Investors/R&D Centers

DEEP KNOWLEDGE ANALYTICS



100 AI Companies: Regional Proportion



The US is still firmly in the lead in terms of its proportion of AI for Drug Discovery companies. Interestingly, Asia currently has the fifth-lowest proportion of AI for Drug Discovery companies. The Asia-Pacific region has, however, begin to aggressively increase their activity in the space in terms of investments into foreign companies (largely US-based companies), and we can expect to see an increase in the number of AI for Drug Discovery Companies located in the Asia-Pacific region generally, and in China particularly.

220 Investors: Regional Proportion



The US still leads the rest of the world in the proportion of AI for Drug Discovery Investors. This is sensible given that they also have the largest proportion of AI for Drug Discovery companies. However, it is interesting to note that, while the UK is home to the second-largest proportion of investors in this space, Asia has now overtaken the EU is rapidly advancing to acquire the #2 position. This past year has seen a substantial increase in the number of Asian investors, as well as Asian Tech & IT corporations, entering the AI for drug discovery industry.

20 Leading R&D Centers: Regional Proportion



The figure above shows that while the US leads the world in terms of the number of R&D Centers focused on AI for Drug DIscovery, China is rapidly catching up. This makes sense within the context of the recent increase in the number of Chinese investors entering the AI for Drug DIscovery space, and the Chinese government's recent commitment to lead the world in AI by the year 2030.

Top-20 Conferences on AI for R&D and Drug Discovery 2018-2019: Regional Proportion



As can be seen in the figure above, whereas previously the US has dominated the AI for Drug DIscovery conference landscape (which follows naturally from the fact that it also leads in terms of the total number of AI for Drug DIscovery conferences and investors), we have seen a significant increase in the number of AI for Drug Discovery conferences located in the UK and EU.

30 Corporations Applying Advanced AI in Healthcare and Drug Discovery



Combined Capitalization of 15 IT & Tech Corporations vs 15 BioPharma Corporations In Millions of USD



As can be seen in the figure to the left, the combined capitalization of the 15 BioPharma corporations profiled in this report have remained on the same level for the past 5 years while the capitalization of the 15 IT & Tech corporations profiled in this report is growing significantly.

This can be considered as evidence that the BioPharma industry is stagnating in general, while the IT & Tech industry is progressing.

This is why it is so notable that the number of IT corporations has already matched the number of BioPharma corporations active in this subsector.

15 IT&Tech Corporations
15 BioPharma Corporations

Source: Deep Knowledge Analytics

Top 20 Global AI for Drug Discovery Conferences



Top 20 Global AI for Drug Discovery Conferences

ARTIFICIAL INTELLIGENCE for DRUG DISCOVERY

May 23, 2018
DoubleTree Suites Boston-Cambridge
Cambridge, MA

BASEL LIFE

11–14 September 2018
Congress Center Basel
Switzerland

WELCOME | BASEL LIFE | EMBO AT BASEL LIFE | ORGANISE YOUR ATTENDANCE | PROGRAMME | ABSTRACTS | INFORMATION | PAST CONFERENCES

Artificial intelligence and blockchain in healthcare

11th & 12th July 2018,
Canary Riverside Plaza Hotel,
London UK

OXFORD GLOBAL

2nd Annual Artificial Intelligence in Drug Development Congress
20-21 September 2018, London, UK

Global Engage

2ND GLOBAL PHARMA R&D INFORMATICS & AI CONGRESS

29-30 OCTOBER 2018 – LONDON, UK

AI PHARMA INNOVATION DRUG DISCOVERY

ARTIFICIAL INTELLIGENCE IN PHARMA INDUSTRY SUMMIT

ARTIFICIAL INTELLIGENCE
TRANSFORMING PHARMA R&D

MAX PLANCK ALUMNI ASSOCIATION

Artificial Intelligence and Big Data in Pharma

Impact on drug development on the role of the industry

March 21, 2018
Max Planck Institute of Biochemistry, Munich

Artificial Intelligence in Drug Development Congress
27-28 September 2017, London, UK

AI Companies in Longevity

Atomwise

BioAge

Insilico Medicine
Aging.AI 2.0

One of the most promising projects developed by Insilico Medicine is called Aging.AI 2.0, which is an AI-empowered platform integrating multiple predictors of clints age and used to track changes of health over time and optimize clints lifestyle.

http://young.ai/

Track your age at every level!



See what makes you younger or older!



Stay young!

Insilico Medicine Earns Accolades from Frost & Sullivan

5 Mega Trends to Disrupt the BioTech & BioMedicine Industries in the next 5 Years



I AI in Healthcare

II Blockchain in Healthcare

III Longevity & Geroscience

IV AgeTech

V Novel Financial Systems

Consequence:
The Major Shift in the BioMedicine Industry



Convergence of 5 Mega Trends



P3 medicine



It is expected that personalized and preventive approaches in the treatment of chronic diseases will become the prevalent one by 2026.

The changes in healthcare systems together with emerging technologies will double the P3 medicine market by 2022.



Source:
https://www.grandviewresearch.com/industry-analysis/personalized-medicine-market

AI FOR
DRUG DISCOVERY,
BIOMARKER DEVELOPMENT
AND ADVANCED R&D
LANDSCAPE OVERVIEW
2018 / Q2

Section III

Comparative Industry Analysis Classification Framework (Investor and M&A Guide)

www.dkv.global/analytics



DEEP
KNOWLEDGE
ANALYTICS

Table of Contents

Comparative Industry Analysis Classification Framework (Investor and M&A Guide)

Section III: Comparative Industry Analysis & Classification Framework (Investor and M&A Guide) is devoted to an in-depth comparative and quantitative analysis of the entire AI for Drug Discovery landscape, specifically tuned for investors and business analysts who wish to gain a deeper understanding of the industry in Q2 of 2018.

- **Chapter XI: Classification/Ratings of AI for Advanced R&D and Drug Discovery Companies** performs a quantitative analysis of many of the AI for Drug Discovery companies covered and profiled in this report using of a variety of tangible metrics that can be used to acquire an understanding of their level of scientific validation and industry activity, including the proportion of AI specialists among their total staff, number of publications, number of patents, etc. It then uses these metrics to rank AI for Drug Discovery companies side by side, and to build a classification framework by which these companies can be better categorized according to their specific focus, application and industry segmentation.

- **Chapter XII: 2010 - 2016 - Investment Rounds, M&A Deals and Notable Events** summarizes some of the most notable investment rounds, M&As and other notable events from 2010-2016, including but not limited to Benevolent AI's $87M raise, ThoughtSpot's $100M raise and Meta's $23M raise.

- **Chapter XIII: 2017 - Investment Rounds, M&A Deals and Notable Events** summarizes some of the most notable investment rounds, M&As and other notable events in 2017, including but not limited to Exscientia's €250M raise, AICure's $15M raise and Insilico Medicine's $10M raise.

- **Chapter XIV: Q1 2018 - Investment Rounds, M&A Deals and Notable Events** summarizes some of the most notable investment rounds, M&As and other notable events in Q1 of 2018, including but not limited to AtomWise's $45M raise, XtalPi's $15M raise, and twoXAR's $10M raise.

- **Chapter XV: Q2 2018 - Investment Rounds, M&A Deals and Notable Events** summarizes the major investments, M&As and other notable events (e.g. joint ventures, public announcements, etc.) that have occurred within the AI for Drug Discovery space specifically in Q2 of 2018, including but not limited to ThoughtSpot's $145M raise, Benevolent.AI's $115M raise, Celsius Therapeutics' $65M raise, and Datavant's $40.5M raise

Chapter XI

Comparison of Leading AI Companies

Comparison of Top-20 AI for Drug Discovery Companies

Funding, $m *(as of 1 July 2018)*



Source: Crunchbase, Google
Securities and Exchange Commission

Comparison of Top-20 AI for Drug Discovery Companies

Number of Scientific Publications



Source: Company Website and PubMed

Comparison of Top-20 AI for Drug Discovery Companies



Source: patents.google.com

Comparison of Top-20 AI for Drug Discovery Companies

Total Number of Employees / AI experts



Source: According to LinkedIn

AI experts vs BioTech experts vs Administrative Staff



Source: Deep Knowledge Analytics

Comparison of Top-20 AI for Drug Discovery Companies

True AI companies
The ratio: AI experts vs
Total Number of Employees



Source: According to LinkedIn

Comparison of Top-20 AI for Drug Discovery Companies

Company	Scientific publications covering AI for Drug Discovery	Number of AI experts in the team / total number of employees	Public talks on AI for Drug Discovery	Validation
Atomwise	+	11/13	+	n/a
Benevolent.AI	+	18/74	+	n/a
Deep Genomics	+	10/26	-	n/a
Exscientia	+	2/12	+	+
GNS Healthcare	+	21/98	-	n/a
Insilico Medicine	+	24/43	+	+
NuMedii	+	4/9	+	+
Numerate	-	4/15	+	+
Recursion Pharmaceuticals	+	85/12	+	+
twoXAR	+	1/15	+	+

Comparison of Top-20 AI for Drug Discovery Companies

Company	Scientific publications covering AI for Drug Discovery	Number of AI experts in the team / total number of employees	Public talks on AI for Drug Discovery	Validation
Berg LLC	-	3/11	+	n/a
Mind the Byte	-	2/33	+	n/a
Biovista	+	1/19	+	+
AiCure	-	9/43	+	+
Cloud Pharmaceuticals	+	1/8	+	n/a
e-therapeutics	+	4/25	+	n/a
Nuritas	-	2/33	+	+
XtalPi	-	1/25	+	n/a
Cyclica	-	7/27	+	+
BioXcel	-	4/88	+	+

Comparison of Top-20 AI for Drug Discovery Companies

Companies	Computation method	Data Type
Atomwise	DL	Chemical notations; QSAR
Benevolent.AI	ML, DL, symbolic AI	Text; images; EHRs; omics
Deep Genomics	n/a	n/a
Exscientia	ML	Chemical notations; high-content screening; SAR
GNS Healthcare	ML	n/a
Insilico Medicine	DL, GANs, GANs + RL, symbolic AI	Omics; EHR
NuMedii	Big data analysis, DL, ML	Raw human, biological, pharmacological and clinical data, normalized and annotated.
Numerate	AI, cloud computing	Chemical notations; screening; high-content screening;
Recursion Pharmaceuticals	n/a	Images, high content screening data
twoXAR	n/a	Omics data, high content screening

Comparison of Top-20 AI for Drug Discovery Companies

Companies	Computation method	Data Type
Berg LLC	DL	Human Data
Mind the Byte	Big Data	protein ligand interactions
Biovista	ML	correlations between drugs, molecular targets, pathways, adverse events and diseases
AiCure	ML	n/a
Cloud Pharmaceuticals	legacy ML, cheminformatics	Chemical notations
e-therapeutics	Big Data	Chemical notations
Nuritas	DL	n/a
XtalPi	Quantum physics; machine learning; cloud computing	n/a
Cyclica	AI	Chemical notations
BioXcel	ML	n/a

Comparison of Top-20 AI for Drug Discovery Companies

Expertise in AI for Drug Discovery
R&D / AI



Comparison of Top-20 AI for Drug Discovery Companies



Classification of AI applications for R&D and Drug Discovery process

Data Mining	Biology Research	Drug Discovery			Drug Development	Biomarker Discovery
		Compound Generation	Compound Binding	ADME/Tox Predictions		
		Atomwise	Atomwise			
benevolent.ai				benevolent.ai		
deep genomics						deep genomics
		exscientia	exscientia	exscientia		
					GNS HEALTHCARE	
	INSILICO MEDICINE	INSILICO MEDICINE	INSILICO MEDICINE	INSILICO MEDICINE	INSILICO MEDICINE	INSILICO MEDICINE
						NuMedii
		Numerate		Numerate		
		RECURSION				
	twoXAR	twoXAR				

Classification of AI applications for R&D and Drug Discovery process

Data Mining	Biology Research	Drug Discovery			Drug Development	Biomarker Discovery
		Compound Generation	Compound Binding	ADME/Tox Predictions		
					AiCure	
	NURITAS					
	e-therapeutics					
		Biovista				
	BERG	BERG				BERG
		CloudPharmaceuticals				
			CYCLICA			
	Mind the Byte		Mind the Byte			
			BioXcel			
				XtalPi		

Competitive Landscape

Hypothesis Knowledge Discovery	Target ID Biology	Compound Generation	Compound Binding	ADME Tox	Clinical Trials	Personalized Medicine	Real World Insights
INSILICO MEDICINE	INSILICO MEDICINE	INSILICO MEDICINE	INSILICO MEDICINE	INSILICO MEDICINE	INSILICO MEDICINE	INSILICO MEDICINE	INSILICO MEDICINE
BenevolentAI	twoXAR	BenevolentAI	Exscientia DRIVEN BY KNOWLEDGE	Exscientia DRIVEN BY KNOWLEDGE	BenevolentAI	IBM Watson	IBM Watson
IBM Watson	NuMedii	inSilico.com	Atomwise	Numerate	IBM Watson	FOUNDATION MEDICINE	nference
SPARKBEYOND	BIOAGE		CYCLICA		SPARKBEYOND	flatiron	Qrativ
nference	Standigm		SCHRÖDINGER		WuXiNextCODE	freenome	iCarbonX 碳云智能
	BERG		XtalPi		DEEP 6	GRAIL	SPARKBEYOND
	deep genomics				Mendel.ai	verily	
	RECURSION				trials.ai	iCarbonX 碳云智能	
	WuXiNextCODE				OWKIN	Over 1000 companies worldwide	
	healx						
	iCarbonX 碳云智能						

Most Promising Players

Corporations

AI companies

Deep Knowledge Analytics (DKA) Disclaimer

The information and opinions in this report were prepared by Deep Knowledge Analytics. The information herein is believed by DKA to be reliable but DKA makes no representation as to the accuracy or completeness of such information. There is no guarantee that the views and opinions expressed in this communication will come to pass. DKA may provide, may have provided or may seek to provide advisory services to one or more companies mentioned herein. In addition, employees of DKA may have purchased or may purchase securities in one or more companies mentioned in this report. Opinions, estimates and analyses in this report constitute the current judgment of the author as of the date of this report. They do not necessarily reflect the opinions of DKA and are subject to change without notice. DKA has no obligation to update, modify or amend this report or to otherwise notify a reader thereof in the event that any matter stated herein, or any opinion, estimate, forecast or analysis set forth herein, changes or subsequently becomes inaccurate. This report is provided for informational purposes only. It is not to be construed as an offer to buy or sell or a solicitation of an offer to buy or sell any financial instruments or to participate in any particular trading strategy in any jurisdiction.